Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients

NCT03671850 is registered in ClinicalTrials.gov with ViGenCell Inc. as lead sponsor.

NCT NCT03671850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03671850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients
Lead sponsor
ViGenCell Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
April 9, 2019
Completion date
June 3, 2024
Enrollment
48 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk/t-cell lymphoma